These agents could be beneficial, e.g., in the treatment of prostate cancer, since AKR1C3 and 17β HSD3 are frequently linked to this condition [53,54], and malignant tumors are usually surrounded by a proinflammatory microenvironment [55]. The gene discussed is AKR1C3; the disease is Familial prostate cancer.